Products for Multi-Modal Regenerative Clinics
Regulatory Notice: ExaVeyra Sciences is a B2B wholesale supplier. Product descriptions are for procurement and research context only and are not therapeutic claims or treatment recommendations.
Regenerative medicine clinics often combine biologics, research peptides, PRP systems, and device-based workflows. ExaVeyra centralizes documentation, wholesale procurement, and cold-chain logistics for approved clinical accounts.
cGMP extracellular vesicle supply with COA review, particle characterization, and cold-chain fulfillment.
Research-grade BPC-157 and TB-500 options through licensed compounding pharmacy partners.
Closed-system device workflows for clinics that offer in-office autologous regenerative procedures.
Chemist-guided review of lot records, sterility, endotoxin, mycoplasma, and identity documentation.
Temperature-controlled fulfillment for biologics and practice-ready shipping coordination.
Account management for reorder planning, documentation requests, and technical product questions.
Documentation-First Procurement for Regenerative Practices
ExaVeyra supports clinics that need transparent sourcing, pharmacy partner clarity, and lot-specific documentation before a product enters their practice workflow.
Building a Documentation-First Regenerative Medicine Supply Chain
Why cGMP matters for extracellular vesicles
Current Good Manufacturing Practice (cGMP) regulations define the minimum quality standards for pharmaceutical manufacturing, including process validation, environmental monitoring, personnel qualification, and batch release testing. For extracellular vesicle preparations, cGMP compliance means the manufacturing environment is controlled, the process is documented and reproducible, and each lot is released only after meeting defined specifications. ExaVeyra sources exclusively from FDA-registered cGMP facilities and requests process validation documentation as part of supplier qualification.
503A versus 503B: what regenerative clinics need to know
503A pharmacies prepare patient-specific compounded prescriptions under state board oversight. 503B outsourcing facilities manufacture larger batches under FDA oversight and can supply office-use quantities without patient-specific prescriptions. The distinction matters because it affects what documentation is required, what FDA oversight applies, and what indications and quantities are permissible. Regenerative medicine clinics that need consistent lot-to-lot supply of research peptides for office use should understand which category their supplier operates under.
Endotoxin testing is non-negotiable for injectable-adjacent biologics
Endotoxins are lipopolysaccharide fragments from gram-negative bacterial cell walls that cause fever and inflammatory responses at very low concentrations. For any biologic that will be used in proximity to compromised skin barriers or research injection protocols, endotoxin content must be quantified using a validated limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay. An endotoxin result of "pass" without a stated acceptance limit and assay method provides no basis for independent verification. ExaVeyra requests quantitative endotoxin data with stated acceptance criteria for every lot.
What a full COA library looks like
A complete COA library for a regenerative medicine practice should include, for each product category: particle concentration and size distribution (for EVs), potency assay with methodology (for peptides), sterility testing under USP <71> or equivalent, endotoxin quantification with acceptance criteria, mycoplasma screening results, identity confirmation by mass spectrometry or HPLC, and lot traceability from the manufacturing batch record. ExaVeyra builds this documentation set during supplier onboarding and makes it available to approved accounts on request.
Benn Bluestein-Veyra, M.Sc. Organic Chemistry. Founder, ExaVeyra Sciences.
Recommended for Regenerative Medicine Clinics
All products require NPI verification and approved wholesale account. COA, lot documentation, and shipping guidance are available for approved practices.
Biomolecular Signaling Vesicles
cGMP MSC-derived extracellular vesicle preparations with lot-specific COA documentation and cold-chain fulfillment.
BPC-157 (Research)
503A-compounded research peptide option for licensed practitioner research protocols. Third-party tested with COA per lot.
TB-500 (Research)
Research-grade peptide supplied through licensed pharmacy partners for approved clinical research workflows.
PRP/PRF Kit
Closed-system PRP and PRF device options for in-office regenerative medicine protocols and procedural workflows.
A Supply Chain Built for Regenerative Practices
M.Sc. Chemist Review
Supplier documentation is evaluated through a technical, chemistry-led review process.
NPI-Verified Access
Wholesale access is limited to licensed practitioners and approved clinical entities.
COA Per Lot
Lot-specific documentation supports internal review and procurement records.
Cold-Chain Fulfillment
Temperature-controlled shipping supports biologic integrity during transit.
503A Partner Network
Research peptides are sourced through licensed compounding pharmacy partners.
Account Management
Approved partners receive reorder planning and documentation support.
Questions from Regenerative Medicine Clinics
What is the difference between 503A and 503B compounding?+
503A pharmacies prepare patient-specific compounded prescriptions under state pharmacy board oversight and are limited to dispensing pursuant to valid prescriptions for identified patients. 503B outsourcing facilities are FDA-registered and can manufacture larger batch quantities for office use without patient-specific prescriptions, under FDA inspection and cGMP requirements. The practical difference for regenerative medicine clinics is that 503B supply supports consistent lot-to-lot office-use procurement, while 503A supply is appropriate for patient-specific compounded preparations. ExaVeyra can help approved clinics understand which pathway applies to their specific procurement needs.
How are ExaVeyra exosomes sourced for regenerative medicine clinics?+
ExaVeyra evaluates extracellular vesicle supplier documentation against the MISEV 2023 framework before approving a lot for distribution. The evaluation includes cGMP facility registration, source material traceability, NTA particle count and size distribution methodology, surface marker identification panel, sterility testing under USP <71> or equivalent, mycoplasma screening, endotoxin quantification with acceptance criteria, and identity marker confirmation. Approved lots are supplied with this documentation available for clinic review. The evaluation is conducted by our founder, an M.Sc. organic chemist with analytical chemistry and biochemistry expertise.
What COA documentation is included with regenerative medicine products?+
COA documentation for regenerative medicine products may include NTA particle concentration and size distribution (for extracellular vesicles), potency assay with methodology (for peptides and small molecules), sterility testing results, mycoplasma screening results, endotoxin quantification with acceptance criteria, identity confirmation by HPLC or mass spectrometry, manufacturing date and lot number, expiration dating, and shipping validation records where applicable. The specific documentation available varies by product category and lot. Approved accounts can request the full documentation package for any product before placing an order.
What is the minimum order for regenerative medicine clinics?+
Minimum order quantities vary by product category, format, and lot availability. Extracellular vesicle preparations are supplied in liquid format and have MOQs set by the manufacturing batch size. Research peptides have MOQs set by the compounding pharmacy partner and may vary by state availability. PRP and PRF device kits are available in standard case quantities. Apply for NPI-verified wholesale access to receive current MOQ, tiered pricing, and volume discount information for your practice volume and product mix.
How do biologics ship to regenerative medicine clinics?+
Liquid extracellular vesicle preparations ship cold-chain in temperature-monitored packaging with expedited fulfillment. Research peptide compounds ship cold-chain for sterile preparations and ambient for lyophilized formats depending on the specific compound and lot. PRP and PRF device kits ship ambient via standard carrier. Shipping requirements and cold-chain configuration are confirmed per order by your account manager.
Can regenerative medicine clinics get protocol support?+
Approved wholesale partners receive a dedicated account manager and can coordinate technical documentation questions with our chemist team. ExaVeyra does not provide medical advice, clinical protocols, or treatment recommendations. Clinical decisions, patient selection, protocol design, and regulatory compliance for specific procedures remain the responsibility of the licensed practitioner. Our support covers procurement, documentation, and supply chain questions.